Skip to main content

Table 4 Relationship between immunochemical features and tumor stage

From: Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature

Target expression Ta Tis (CIS) T1 T2 >T3, N+ or M+ p-value Target expression Ta Tis (CIS) T1 T2 >T3, N+ or M+ p-value
VEGFA        APOE       
1 10 (25.0%) 5 (29.4%) 18 (33.3%) 6 (25.0%) 8 (28.6%) 0.670 1 13 (27.7%) 1 (6.3%) 9 (15.3%) 7 (24.1%) 0 (0%) 0.009
2 6 (15.0%) 5 (29.4%) 17 (31.5%) 6 (25.0%) 9 (32.1%)   2 14 (29.8%) 6 (37.5%) 14 (23.7%) 5 (17.2%) 5 (13.9%)  
3 10 (25.0%) 4 (23.5%) 9 (16.7%) 7 (29.2%) 7 (25.0%)   3 10 (21.3%) 5 (31.3%) 13 (22.0%) 6 (20.7%) 17 (47.2%)  
4 14 (35.0%) 3 (17.6%) 10 (18.5%) 5 (20.8%) 4 (14.3%)   4 10 (21.3%) 4 (25.0%) 23 (39.0%) 11 (37.9%) 14 (38.9%)  
MMP9        SERPINA1       
1 5 (11.6%)   4 (7.1%) 4 (13.8%)   0.036 1 11 (25.0%) 2 (13.3%) 16 (27.6%) 3 (10.7%) 2 (5.9%) 0.036
2 15 (34.9%) 5 (35.7%) 16 (28.6%) 4 (13.8%) 5 (14.3%)   2 10 (22.7%) 2 (13.3%) 12 (20.7%) 9 (32.1%) 4 (11.8%)  
3 13 (30.2%) 5 (35.7%) 22 (39.3%) 7 (24.1%) 11 (31.4%)   3 10 (22.7%) 4 (26.7%) 19 (32.8%) 6 (21.4%) 9 (26.5%)  
4 10 (23.3%) 4 (28.6%) 14 (25.0%) 14 (48.3%) 19 (54.3%)   4 13 (29.5%) 7 (46.7%) 11 (19.0%) 10 (35.7%) 19 (55.9%)  
MMP10        SDC1       
1 11 (25.6%) 8 (57.1%) 12 (21.8%) 2 (6.9%) 3 (8.3%) 0.036 1 6 (14.3%) 4 (21.1%) 5 (8.5%) 5 (17.2%) 7 (20.0%) 0.021
2 9 (20.9%) 2 (14.3%) 10 (18.2%) 8 (27.6%) 6 (16.7%)   2 9 (21.4%) 6 (31.6%) 5 (8.5%) 8 (27.6%) 6 (17.1%)  
3 10 (23.3%) 3 (21.4%) 12 (21.8%) 9 (31.0%) 11 (30.6%)   3 13 (31.0%) 6 (31.6%) 17 (28.8%) 8 (27.6%) 16 (45.7%)  
4 13 (30.2%) 1 (7.1%) 21 (38.2%) 10 (34.5%) 16 (44.4%)   4 14 (33.3%) 3 (15.8%) 32 (54.2%) 8 (27.6%) 6 (17.1%)  
SERPINE1        ANG       
1 19 (45.2%) 8 (53.3%) 12 (21.4%) 2 (7.1%) 3 (8.6%) 0.0003 1 0 (0%) 1 (5.9%) 0 (0%) 3 (10.3%) 0 (0%) <0.0001
2 7 (16.7%) 1 (6.7%) 11 (19.6%) 4 (14.3%) 8 (22.9%)   2 23 (50.0%) 8 (47.1%) 16 (27.1%) 6 (20.7%) 1 (2.8%)  
3 9 (21.4%) 5 (33.3%) 15 (26.8%) 5 (17.9%) 9 (25.7%)   3 12 (26.1%) 2 (11.8%) 24 (40.7%) 10 (34.5%) 15 (41.7%)  
4 7 (16.7%) 1 (6.7%) 18 (32.1%) 17 (60.7%) 15 (42.9%)   4 11 (23.9%) 6 (35.3%) 19 (32.2%) 10 (34.5%) 20 (55.6%)  
IL8              
1 19 (41.3%) 7 (43.8%) 20 (33.3%) 4 (13.8%) 2 (5.4%) 0.001        
2 12 (26.1%) 3 (18.8%) 16 (26.7%) 4 (13.8%) 6 (16.2%)         
3 6 (13.0%) 1 (6.3%) 11 (18.3%) 10 (34.5%) 8 (21.6%)         
4 9 (19.6%) 5 (31.3%) 13 (21.7%) 11 (37.9%) 21 (56.8%)         
CA9              
1 12 (26.7%) 4 (23.5%) 10 (16.7%) 7 (24.1%) 2 (5.3%) 0.308        
2 12 (26.7%) 5 (29.4%) 9 (15.0%) 6 (20.7%) 14 (36.8%)         
3 9 (20.0%) 3 (17.6%) 17 (28.3%) 6 (20.7%) 10 (26.3%)         
4 12 (26.7%) 5 (29.4%) 24 (40.0%) 10 (34.5%) 12 (31.6%)